Curaleaf Clinic

Today the Sapphire Access Scheme expands to offer £50 appointments to patients. This significant saving marks the success of the UK Medical Cannabis Registry in publishing Real World Evidence in #medicalcannabis Head of Research and Access, Dr Simon Erridge, commented “As a multi-award-winning medical cannabis clinic, we are delighted to further improve access to this treatment option where other therapies haven’t worked. By collecting patient reported outcomes and producing peer reviewed analysis in return, together we inform the wider evidence base of the efficacy and safety of medical cannabis, which is essential for ensuring the correct patients are able to access treatment.” Read more about this news https://lnkd.in/gV3Dq5pu

At Curaleaf Clinic, we’re proud to lead the way in medical cannabis research. With the help of our patients and the UK Medical Cannabis Registry, we’re able to share research that will help shape the future of medical cannabis globally.    This week, Dr Simon Erridge, Research Director at Curaleaf Clinic, and Dr Mikael Sodergren, Chief Medical Officer at Curaleaf International, are attending the 34th Annual International Cannabinoid Research Society (ICRS) Symposium on Cannabinoids, where they will showcase the latest research from the UK Medical Cannabis Registry.    Read our blog to learn more: https://lnkd.in/eq-2P9WE    #MedicalCannabisUK #ICRS2024 

Curaleaf at Cannabis Europa 2024: What matters to patients? As part of the leading medical cannabis company in Europe, we were thrilled to be the headline sponsors of the Cannabis Europa conference in London. This year's event brought together key players in the industry. In particular, Curaleaf International's spokespeople took the stage to discuss key developments in the European cannabis landscape. Cannabis Europa is one of the leading international conferences where global leaders, innovators, and stakeholders come together annually to explore the latest advancements and regulatory shifts shaping the cannabis industry. Here are the highlights from this industry conference, along with the key takeaways for patients: Raising Awareness in the UK: The UK panel highlighted the need for greater awareness that medical cannabis can be legally prescribed. Curaleaf’s own Jonathan Hodgson emphasised the need for collaboration across the industry to make this happen. Germany's Cannabis Legalisation: Industry experts explored Germany's recent change in cannabis legislation and the removal of cannabis from the narcotics list. They explored how this would reduce barriers to access for patients and its implications for public safety. Commitment to Innovation: Throughout the conference, the importance of research and development was highlighted to ensure that patients are able to access a diverse range of medicines to meet their needs. Changes in Germany and the US are expected to accelerate research which will only help improve patient care here in the UK. Leading the way: At the Business of Cannabis | Europe Awards, Curaleaf International won a total of four awards, including Clinic of the Year. Curaleaf Clinic’s commitment to research, raising awareness, and patient care were all highlighted as reasons why we were recognised with this award. With ongoing advancements and collaborative efforts, we look forward to seeing continued improvements to not only patient access but the care they receive across the industry. #CannabisEuropa #CuraleafInternational #MedicalCannabis #CannabisIndustry #GlobalHealth #InnovationInCannabis

We are pleased to share that our researchers have won the ‘NPPR Article Award 2023’ from the Japanese Society of Neuropsychopharmacology for research conducted using the UK Medical Cannabis Registry.   It is pleasing to see our continued commitment to advancing the evidence on the effects of medical cannabis recognised in this way. Thank you to all our patients who have signed up to the Curaleaf Access Scheme and contribute to the registry - helping us further medical cannabis research together!   Learn more about our research here: https://lnkd.in/eTiKxMYH

We were featured in a recent article by the Mirror alongside Dr. Emeka Okorocha, Dr Simon Erridge, Research Director at Curaleaf Clinic, and our patient Jenn. The article delves into our health desperation campaign, shedding light on the extreme measures individuals are driven to in their battle against chronic pain.   Our campaign is aimed at raising awareness about medical cannabis as an alternative option for those battling chronic pain who haven’t responded to first-line treatments, as shockingly, only 52% of the UK population are aware of its legal availability for medical use.   Dr Emeka Okorocha said: “It’s disheartening to see so many people resorting to extreme measures in an attempt to alleviate their suffering, often with minimal relief. When conventional treatments don’t work, it’s important to explore alternative therapies, but to do so with the input from trained medical professionals. Embracing non-traditional approaches offers hope for those in desperate need, promising relief where conventional methods might have fallen short.”   Read the full article here: https://lnkd.in/eW4aT9_V

The recent BBC News article addresses the national shortage of ADHD medication, which has left thousands of individuals with ADHD unable to access their medication. Amid this shortage, the article covers the rise in patients with ADHD seen at Curaleaf Clinic, and our latest research. At Curaleaf Clinic we have seen a rise in the number of patients we see with attention-deficit/hyperactivity disorder (ADHD) over the past year. Dr Simon Erridge, Research Director at Curaleaf Clinic, discussed the rise in patient numbers with the BBC: "A lot of people with ADHD may try a number of different medications to find the one that works best for them, if that is suddenly taken away by shortages it's only natural for people to explore other options and there's no reason why that might not include medical cannabis." Read the full article here: https://bbc.in/3TeJ9vh Read our latest research on the outcomes in patients with ADHD who had been enrolled on the UK Medical Cannabis Registry for at least 12 months here: https://bit.ly/4bSuCwz

We were thrilled to see Curaleaf Clinic's patient, Chris Cowan, and consultant, Dr Wendy Holden, featured in The Guardian's article yesterday. Chris shares his transformative journey from illicit to legal cannabis use and the impact this has had on his life, ‘when I found this clinic, I transitioned from being criminalised to becoming a normal member of society.' Dr Wendy Holden highlighted how attitudes towards medical cannabis are improving within the medical community, stating, ‘We're moving towards making judgments based on evidence, not prejudice and preconceptions.' Read the full interviews with Chris and Dr Holden here:

We are pleased to announce that Sapphire Clinics has now officially rebranded as Curaleaf Clinic! As part of this rebranding, we will have a new look and feel to our website and socials and our email addresses will be updated to align with the Curaleaf domain. If you have any questions or need assistance, our patient support team is here for you at our new address: [email protected] We deeply appreciate your trust and look forward to continuing to serve you under our new name, Curaleaf Clinic.   Learn more about our rebrand and how it might impact you on our website: https://lnkd.in/eyu9-t67

We’re excited to announce that on the 8th January 2024, Sapphire Clinics will officially transition to its new identity as Curaleaf Clinic! The rebranding primarily impacts external elements, including the website and external communications. Patients will continue to receive care from the same dedicated team.    We understand that change can raise questions, if you need any further information about this rebranding, our Patient Support Team is on hand to answer your questions.      We deeply appreciate your trust and look forward to ringing in 2024 as Curaleaf Clinic.     Learn more about our rebrand and how it might impact you on our website: https://lnkd.in/eyu9-t67  

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders, with an estimated global prevalence of 5% in children and 2.5% in adults. ADHD is often associated with a higher incidence of sleep disturbance and psychiatric co-morbidities, including anxiety, substance misuse, and depression. As a result, these issues can significantly reduce the quality of life for individuals with ADHD. There is a lack of high-quality clinical evidence and prospective studies on CBMPs in patients with ADHD-related symptoms. Importantly, there are no published clinical studies of long-term outcomes to assess the efficacy and safety of adult patients treated with CBMPs. Our new study therefore aimed to analyse the health-related quality of life and safety outcomes in ADHD patients who are prescribed cannabis-based medicinal products and have enrolled in the UK Medical Cannabis Registry. Read the full study here: https://bit.ly/3RvmVEp